# Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

> **NCT05359653** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 74 (estimated)

## Conditions studied

- Multiple Sclerosis (MS)
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Primary Progressive
- Multiple Sclerosis, Chronic Progressive
- Multiple Sclerosis Relapse
- Multiple Sclerosis Brain Lesion
- Multiple Sclerosis Benign

## Interventions

- **DRUG:** Clemastine Fumarate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05359653
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-01
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-06-01
- **Target enrollment:** 74 (ESTIMATED)
- **Last updated:** 2026-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05359653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05359653, "Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05359653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*